GLP-1 drugs are moving into a new area of investor interest: cancer. Originally developed for Type 2 diabetes and now widely known for obesity and weight management, these therapies are being studied for their possible role in oncology. The evidence is still early, but research discussed at ASCO 2026 suggests the class may have relevance beyond metabolic disease.
If GLP-1s show credible links to better cancer outcomes, even as part of a wider treatment or prevention strategy, the commercial and strategic implications could be significant. The current data does not prove that these drugs prevent cancer progression, but it gives researchers and companies a reason to look more closely.
One study reviewed more than 12,000 patients across seven obesity-related cancers. It compared people taking GLP-1 receptor agonists with people taking DPP-4 inhibitors, another treatment used in Type 2 diabetes. The researchers found lower rates of progression to Stage IV disease among GLP-1 users. The strongest signals were seen in breast cancer, non-small cell lung cancer, colorectal cancer and liver cancer, specifically hepatocellular carcinoma. Across these cancer types, GLP-1 users were reported to have a 38% to 50% lower likelihood of progression to Stage IV disease than the comparison group.
The research was observational, which means it can show a relationship, but it cannot prove cause and effect. The lower progression rates could be linked to weight loss, better metabolic health, differences between patient groups or other factors. The path from early data to clinical practice is long, expensive and uncertain.
Large pharmaceutical companies, oncology specialists and healthcare data groups will be watching whether further research supports the same direction. If it does, GLP-1s could become part of a wider discussion about cancer risk, cancer progression and metabolic intervention. That would expand the strategic value of the class and could influence research spending, partnerships and trial design.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
